Market Access & HEOR Consulting

US-based economic consulting firm with published outcomes and cost-effectiveness analyses on esketamine treatment pathways relevant to payer decision-making and market access strategy.

Economic and strategy consultancy with life sciences advisory services, including published analysis on the evolving psychedelic therapeutics landscape and market implications.

Delphi is a psychedelic healthcare consultancy focused on responsible integration into mainstream care. Led by Lia Mix and a cross-sector team, Delphi supports healthcare providers, investors, government agencies, and psychedelic organisations with strategy, education, and implementation guidance across regulation, delivery, and reimbursement. A major Delphi initiative is IHPI (Ibogaine Healthcare Policy Institute), a neutral, evidence-based, implementation-focused institute that develops coverage playbooks, health-economics models, and delivery blueprints for safe ibogaine adoption. Delphi also leads HOPE (Health Outcomes and Psychedelic Economics), a collaborative effort to generate independent economic evidence that can inform payer policy and broader healthcare access decisions.

Commercial real-world data products and linked evidence assets used in life sciences research and regulatory support.

Global strategy consultancy with US/EU healthcare practices and published analysis on psychedelic treatment pathways, funding dynamics, and commercialization implications.

Global commercialization and market access advisory firm with published commentary on positioning psychedelic medicines within biopharmaceutical development frameworks.

Purpose-led healthcare consultancy focused on integrating psychedelic-assisted therapy into health systems, with explicit services across strategic planning, implementation, reimbursement, and go-to-market execution.